The use of platelet function testing in PCI and CABG patients

Blood Reviews

Volumn 28, Issue 3, 2014, Pages 109-121

  Janssen, Paul W A ^a   ten Berg, Jurriën M ^a   Hackeng, Christian M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Anti platelet therapy; Atherothrombotic events; Bleeding; CABG; PCI; Platelet function testing

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOSTATUS; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT;

ARTICLE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FUNCTION TEST; FUNCTION TEST KIT; HUMAN; MEASUREMENT; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET FUNCTION TEST; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY; TIME TO TREATMENT; BLEEDING; BLOOD; BLOOD CLOTTING PARAMETERS; OPERATIVE BLOOD LOSS; PREDICTIVE VALUE; PROCEDURES;

BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS;

EID: 84900864151     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.03.004     Document Type: Article

References (144)

1. Task Force Members, Montalescot G., Sechtem U., et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013, 34(38):2949-3003.
2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg P.G., James S.K., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33(20):2569-2619.
3. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32(23):2999-3054.
4. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057.
5. Stone G.W., Witzenbichler B., Weisz G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013, 382(9892):614-623.
6. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303(8):754-762.
7. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001-2015.
8. Montalescot G., Bolognese L., Dudek D., et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013, 369(11):999-1010.
9. Stein P.D., Schunemann H.J., Dalen J.E., Gutterman D. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl.):600S-608S.
10. Ferraris V.A., Saha S.P., Oestreich J.H., et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 2012, 94(5):1761-1781.
11. Douketis J.D., Berger P.B., Dunn A.S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl.):299S-339S.
12. Hillis L.D., Smith P.K., Anderson J.L., et al. ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011, 58(24):e123-e210.
13. Zimmermann N., Gams E., Hohlfeld T. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg 2008, 34(1):93-108.
14. Desai N.D., Cohen E.A., Naylor C.D., Fremes S.E., Radial Artery Patency Study Investigators A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 2004, 351(22):2302-2309.
15. Alexander J.H., Hafley G., Harrington R.A., et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005, 294(19):2446-2454.
16. Kulik A., Le May M.R., Voisine P., et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE). Trial Circ 2010, 122(25):2680-2687.
17. Goldman S., Sethi G.K., Holman W., et al. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. JAMA 2011, 305(2):167-174.
18. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009, 360(10):961-972.
19. Lamy A., Devereaux P.J., Prabhakaran D., et al. Effects of off-pump and on-pump coronary-artery bypass grafting at 1year. N Engl J Med 2013, 368(13):1179-1188.
20. Zimmermann N., Wenk A., Kim U., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003, 108(5):542-547.
21. Mulder B.J., van der Doef R.M., van der Wall E.E., et al. Effect of various antithrombotic regimens (aspirin, aspirin plus dipyridamole, anticoagulants) on the functional status of patients and grafts one year after coronary artery bypass grafting. Eur Heart J 1994, 15(8):1129-1134.
22. van der Meer J., Brutel de la Riviere A., van Gilst W.H., et al. Effects of low dose aspirin (50mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1year. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of coronary artery bypass graft occlusion by aspirin, dipyridamole and acenocoumarol/phenprocoumon study. J Am Coll Cardiol 1994, 24(5):1181-1188.
23. Yli-Mayry S., Huikuri H.V., Korhonen U.R., et al. Efficacy and safety of anticoagulant therapy started pre-operatively in preventing coronary vein graft occlusion. Eur Heart J 1992, 13(9):1259-1264.
24. Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997, 336(3):153-162.
25. Mahla E., Suarez T.A., Bliden K.P., et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012, 5(2):261-269.
26. Weber C.F., Gorlinger K., Meininger D., et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012, 117(3):531-547.
27. Bouman H.J., Harmsze A.M., van Werkum J.W., et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011, 97(15):1239-1244.
28. Bergmeijer T.O., ten Berg J.M. Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet. Rev Esp Cardiol (Engl Ed) 2012, 65(3):205-207.
29. Mega J.L., Hochholzer W., Frelinger A.L., et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011, 306(20):2221-2228.
30. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354-362.
31. Sofi F., Giusti B., Marcucci R., Gori A.M., Abbate R., Gensini G.F. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011, 11(3):199-206.
32. Viviani Anselmi C., Briguori C., Roncarati R., et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv 2013, 6(11):1166-1175.
33. Sim S.C., Risinger C., Dahl M.L., et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006, 79(1):103-113.
34. Harmsze A.M., van Werkum J.W., Hackeng C.M., et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012, 22(3):169-175.
35. Sibbing D., Koch W., Gebhard D., et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010, 121(4):512-518.
36. Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56(12):919-933.
37. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54(8):2430-2435.
38. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 2004, 16(4):169-174.
39. Heestermans A.A., van Werkum J.W., Taubert D., et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008, 122(6):776-781.
40. Silvain J., Cayla G., Hulot J.S., et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J 2012, 33(10):1241-1249.
41. Harmsze A.M., Robijns K., van Werkum J.W., et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010, 103(5):920-925.
42. Harmsze A.M., van Werkum J.W., Taubert D., Hackeng C.M., Deneer V.H. Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel's active metabolite. Ann Pharmacother 2011, 45(4):542-543.
43. Sibbing D., von Beckerath N., Morath T., et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 2010, 31(10):1205-1211.
44. Bliden K.P., Dichiara J., Lawal L., et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008, 52(7):531-533.
45. Gurbel P.A., Nolin T.D., Tantry U.S. Clopidogrel efficacy and cigarette smoking status. JAMA 2012, 307(23):2495-2496.
46. Gurbel P.A., Bliden K.P., Logan D.K., et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013, 62(6):505-512.
47. Frelinger A.L., Bhatt D.L., Lee R.D., et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013, 61(8):872-879.
48. Tantry U.S., Bonello L., Aradi D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013, 62(24):2261-2273.
49. Hovens M.M., Snoep J.D., Eikenboom J.C., van der Bom J.G., Mertens B.J., Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007, 153(2):175-181.
50. Gluckman T.J., McLean R.C., Schulman S.P., et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011, 57(9):1069-1077.
51. Grove E.L., Hvas A.M., Johnsen H.L., et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010, 103(6):1245-1253.
52. Frelinger A.L., Li Y., Linden M.D., et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008, 6(12):2035-2044.
53. Patrono C., Baigent C., Hirsh J., Roth G., American College of Chest Physicians Antiplatelet drugs: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl.):199S-233S.
54. Wang Z., Gao F., Men J., Yang J., Modi P., Wei M. Polymorphisms and high on-aspirin platelet reactivity after off-pump coronary artery bypass grafting. Scand Cardiovasc J 2013, 47(4):194-199.
55. Alexopoulos D., Xanthopoulou I., Gkizas V., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012, 5(6):797-804.
56. Bonello L., Mancini J., Pansieri M., et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012, 10(10):1999-2005.
57. Valgimigli M., Tebaldi M., Campo G., et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012, 5(3):268-277.
58. Parodi G., Valenti R., Bellandi B., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013, 61(15):1601-1606.
59. Campo G., Fileti L., de Cesare N., et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010, 56(18):1447-1455.
60. Mangiacapra F., Patti G., Barbato E., et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012, 5(3):281-289.
61. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011, 57(25):2474-2483.
62. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008, 52(14):1128-1133.
63. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29(8):992-1000.
64. Price M.J., Angiolillo D.J., Teirstein P.S., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 2011, 124(10):1132-1137.
65. Suh J.W., Lee S.P., Park K.W., et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011, 57(3):280-289.
66. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119(2):237-242.
67. Gurbel P.A., Bliden K.P., Navickas I.A., et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010, 160(2):346-354.
68. Blindt R., Stellbrink K., de Taeye A., et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007, 98(6):1329-1334.
69. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5(8):1630-1636.
70. Frere C., Cuisset T., Quilici J., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007, 98(4):838-843.
71. Cuisset T., Grosdidier C., Loundou A.D., et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013, 6(8):854-863.
72. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53(10):849-856.
73. Sibbing D., Bernlochner I., Schulz S., et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol 2012, 60(5):369-377.
74. Gurbel P.A., Antonino M.J., Bliden K.P., et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008, 19(8):595-604.
75. Cuisset T., Cayla G., Frere C., et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. EuroIntervention 2009, 5(3):325-329.
76. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011, 306(11):1215-1223.
77. Krasopoulos G., Brister S.J., Beattie W.S., Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336(7637):195-198.
78. Marcucci R., Paniccia R., Antonucci E., et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006, 98(9):1156-1159.
79. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)?. Eur Heart J 2007, 28(14):1673-1675.
80. Tantry U.S., Mahla E., Gurbel P.A. Aspirin resistance. Prog Cardiovasc Dis 2009, 52(2):141-152.
81. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ten Berg J.M., Hackeng C.M. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010, 8(10):2140-2148.
82. Collet J.P., Cuisset T., Range G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012, 367(22):2100-2109.
83. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305(11):1097-1105.
84. Serebruany V., Rao S.V., Silva M.A., et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010, 31(2):227-235.
85. Cayla G., Cuisset T., Silvain J., et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol 2013, 111(1):38-44.
86. Patti G., Pasceri V., Vizzi V., Ricottini E., Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding study). Am J Cardiol 2011, 107(7):995-1000.
87. Mokhtar O.A., Lemesle G., Armero S., et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 2010, 126(2):e147-e149.
88. Grosdidier C., Quilici J., Loosveld M., et al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 2013, 111(7):985-990.
89. Sibbing D., Schulz S., Braun S., et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010, 8(2):250-256.
90. Parodi G., Bellandi B., Venditti F., et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012, 109(2):214-218.
91. Sibbing D., Steinhubl S.R., Schulz S., Schomig A., Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010, 56(4):317-318.
92. Kerneis M., Silvain J., Abtan J., et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv 2013, 6(2):158-165.
93. Mrdovic I., Savic L., Krljanac G., et al. Rationale and design of the on-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial. J Interv Cardiol 2013, 26(3):221-227.
94. Trenk D., Stone G.W., Gawaz M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012, 59(24):2159-2164.
95. Valgimigli M., Campo G., de Cesare N., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 2009, 119(25):3215-3222.
96. Bonello L., Camoin-Jau L., Armero S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103(1):5-10.
97. Wang X., Zhang D., Zhuang S., Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol 2011, 34(5):332-333. [334, 335, 336, 337, 338].
98. Siller-Matula J.M., Francesconi M., Dechant C., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013, 167(5):2018-2023.
99. Paone G., Brewer R., Likosky D.S., et al. Transfusion rate as a quality metric: is blood conservation a learnable skill?. Ann Thorac Surg 2013, 96(4):1279-1286.
100. Ranucci M., Pavesi M., Mazza E., et al. Risk factors for renal dysfunction after coronary surgery: the role of cardiopulmonary bypass technique. Perfusion 1994, 9(5):319-326.
101. Murphy G.J., Reeves B.C., Rogers C.A., Rizvi S.I., Culliford L., Angelini G.D. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007, 116(22):2544-2552.
102. Hongo R.H., Ley J., Dick S.E., Yee R.R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002, 40(2):231-237.
103. Yende S., Wunderink R.G. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001, 29(12):2271-2275.
104. Kapetanakis E.I., Medlam D.A., Boyce S.W., et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?. Eur Heart J 2005, 26(6):576-583.
105. Alstrom U., Granath F., Friberg O., Ekbom A., Stahle E. Risk factors for re-exploration due to bleeding after coronary artery bypass grafting. Scand Cardiovasc J 2012, 46(1):39-44.
106. Christensen M.C., Dziewior F., Kempel A., von Heymann C. Increased chest tube drainage is independently associated with adverse outcome after cardiac surgery. J Cardiothorac Vasc Anesth 2012, 26(1):46-51.
107. Essell J.H., Martin T.J., Salinas J., Thompson J.M., Smith V.C. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993, 7(4):410-415.
108. Spiess B.D., Tuman K.J., McCarthy R.J., DeLaria G.A., Schillo R., Ivankovich A.D. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit 1987, 3(1):25-30.
109. Tuman K.J., Spiess B.D., McCarthy R.J., Ivankovich A.D. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989, 69(1):69-75.
110. Dorman B.H., Spinale F.G., Bailey M.K., Kratz J.M., Roy R.C. Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thromboelastography versus coagulation screen. Anesth Analg 1993, 76(4):694-700.
111. Zisman E., Eden A., Shenderey A., et al. The effect of acute autologous blood transfusion on coagulation dysfunction after cardiopulmonary bypass. Eur J Anaesthesiol 2009, 26(10):868-873.
112. Nuttall G.A., Oliver W.C., Ereth M.H., Santrach P.J. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997, 11(7):815-823.
113. Wang J.S., Lin C.Y., Hung W.T., et al. Thromboelastogram fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 1992, 53(3):435-439.
114. Kwak Y.L., Kim J.C., Choi Y.S., Yoo K.J., Song Y., Shim J.K. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010, 56(24):1994-2002.
115. Ostrowsky J., Foes J., Warchol M., Tsarovsky G., Blay J. Plateletworks platelet function test compared to the thromboelastograph for prediction of postoperative outcomes. J Extra Corpor Technol 2004, 36(2):149-152.
116. Alstrom U., Granath F., Oldgren J., Stahle E., Tyden H., Siegbahn A. Platelet inhibition assessed with VerifyNow, flow cytometry and platelet mapping in patients undergoing heart surgery. Thromb Res 2009, 124(5):572-577.
117. Ereth M.H., Nuttall G.A., Klindworth J.T., et al. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass?. Anesth Analg 1997, 85(2):259-264.
118. Reinhofer M., Brauer M., Franke U., Barz D., Marx G., Losche W. The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis 2008, 19(3):212-219.
119. Cammerer U., Dietrich W., Rampf T., Braun S.L., Richter J.A. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003, 96(1):51-57. [table of contents].
120. Dalen M., van der Linden J., Holm M., Lindvall G., Ivert T. Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2014, 28(2):230-234.
121. Lennon M.J., Gibbs N.M., Weightman W.M., McGuire D., Michalopoulos N. A comparison of plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004, 18(2):136-140.
122. Dalen M., van der Linden J., Lindvall G., Ivert T. Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery. Scand Cardiovasc J 2012, 46(1):32-38.
123. Orlov D., McCluskey S.A., Selby R., Yip P., Pendergrast J., Karkouti K. Platelet dysfunction as measured by a point-of-care monitor is an independent predictor of high blood loss in cardiac surgery. Anesth Analg 2014, 118(2):257-263.
124. Reece M.J., Klein A.A., Salviz E.A., et al. Near-patient platelet function testing in patients undergoing coronary artery surgery: a pilot study. Anaesthesia 2011, 66(2):97-103.
125. Rahe-Meyer N., Winterhalter M., Boden A., et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009, 53(2):168-175.
126. Petricevic M., Biocina B., Milicic D., et al. Bleeding risk assessment using multiple electrode aggregometry in patients following coronary artery bypass surgery. J Thromb Thrombolysis 2013, 35(1):31-40.
127. Keyl C., Kmitta E., Kueri S., Zietak T., Trenk D. Effects of aspirin and desmopressin on platelet reactivity in patients undergoing cardiac surgery with extracorporeal circulation. Thromb Haemost 2011, 105(1):113-121.
128. Solomon C., Hartmann J., Osthaus A., et al. Platelet concentrates transfusion in cardiac surgery in relation to preoperative point-of-care assessment of platelet adhesion and aggregation. Platelets 2010, 21(3):221-228.
129. Lang T., Bauters A., Braun S.L., et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005, 16(4):301-310.
130. Chen L., Bracey A.W., Radovancevic R., et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004, 128(3):425-431.
131. Despotis G.J., Levine V., Filos K.S., et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996, 85(6):1311-1323.
132. Isgro F., Rehn E., Kiessling A.H., Kretz K.U., Kilian W., Saggau W. Platelet function test HemoSTATUS 2: tool or toy for an optimized management of hemostasis?. Perfusion 2002, 17(1):27-31.
133. Ereth M.H., Nuttall G.A., Santrach P.J., Klindworth J.T., Oliver W.C., Schaff H.V. The relation between the platelet-activated clotting test (HemoSTATUS) and blood loss after cardiopulmonary bypass. Anesthesiology 1998, 88(4):962-969.
134. Poston R., Gu J., Manchio J., et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005, 27(4):584-591.
135. Bevilacqua S., Alkodami A.A., Volpi E., et al. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function. Ann Thorac Surg 2009, 87(2):496-502.
136. Rafiq S., Johansson P.I., Zacho M., et al. Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial. Trials 2012, 13. [48-6215-13-48].
137. Kim H.J., Lee J.M., Seo J.H., et al. Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery. J Korean Med Sci 2011, 26(8):1041-1046.
138. Gorlinger K., Dirkmann D., Hanke A.A., et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011, 115(6):1179-1191.
139. Spiess B.D., Gillies B.S., Chandler W., Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995, 9(2):168-173.
140. Shore-Lesserson L., Manspeizer H.E., DePerio M., Francis S., Vela-Cantos F., Ergin M.A. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999, 88(2):312-319.
141. Royston D., von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001, 86(4):575-578.
142. Westbrook A.J., Olsen J., Bailey M., Bates J., Scully M., Salamonsen R.F. Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study. Heart Lung Circ 2009, 18(4):277-288.
143. Ak K., Isbir C.S., Tetik S., et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg 2009, 24(4):404-410.
144. Avidan M.S., Alcock E.L., Da Fonseca J., et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004, 92(2):178-186.